TORONTO, May 19, 2021 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)
(Frankfurt: A2JMZC), a vertically
integrated medical cannabis leader with core operations in
Latin America and Europe, today announces that it will host a
conference call on Friday, May 28,
2021 at 10:00 a.m. Eastern
time to discuss its results for the first quarter ended
March 31, 2021. The Company will
provide its financial results in a press release prior to the
Khiron to Host First Quarter 2021 Conference Call on May 28, 2021
Khiron invites individual and institutional investors, as well
as advisors and analysts, to attend the Company's First Quarter
2021 Conference Call, followed by a Q&A session.
TIME: 10:00am ET/7:00am PT/4:00pm
PRESENTERS: Alvaro Torres, Khiron
Chief Executive Officer and Director, Joel
Friedman, Khiron Chief Financial Officer, and Chris Naprawa, Chairman of Khiron Board of
FORMAT: Live 30 minute presentation & Q&A session
Khiron Retains Investor Relations Providers
Company has retained Stonebridge Partners LLC ("Stonebridge") to
provide investor relations services.
Under the terms of the agreement, the Company has engaged
Stonebridge, for a period of three (3) months with renewal on a
month-to-month basis by mutual agreement only, to provide investor
content communications services to the Company. The Company will
pay Stonebridge a monthly fee of USD$5,000. At the time of this agreement, neither
Stonebridge nor its principals have any direct or indirect interest
in the Company's securities. The engagement of Stonebridge remains
subject to the approval of the TSX Venture Exchange.
About Khiron Life Sciences Corp.
Khiron is a
vertically integrated medical and CPG cannabis company with core
operations in Latin America, and
operational activity in Europe and
North America. Khiron is the
leading medical cannabis provider in Colombia and the first company licensed in
Colombia for the cultivation,
production, domestic distribution and sales, and international
export of both low and high THC medical cannabis products. The
Company has filled medical cannabis prescriptions in Colombia, Peru, Germany
and the United Kingdom, and is
positioned to commence sales in Mexico and Brazil in 2021.
Leveraging wholly-owned medical clinics and proprietary
telemedicine platforms, Khiron combines a patient-oriented
approach, physician education programs, scientific expertise,
product innovation, and agricultural infrastructure to drive
prescriptions and brand loyalty. Its Wellbeing Products unit
launched the first branded CBD skincare brand in Colombia, with Kuida™ now marketed in multiple
jurisdictions in Latin America,
the US and United Kingdom. The
Company is led by Co-founder and Chief Executive Officer,
Alvaro Torres, together with an
experienced and diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
T: +1 (647) 556-5750
Vice President, Communications
View original content to download
SOURCE Khiron Life Sciences Corp.